Clinical trials: Postmenopausal Osteoporosis
Osteoporosis
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with…
- Trial name
- NCT00479037
- Testing
- Full Length Parathyroid Hormone, PTH(1-84), Strontium Ranelate
- Where
- Denmark
- Volunteers
- 82 people
- Sponsor
- Nycomed
Osteoporosis
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in…
- Trial name
- NCT05067335
- Testing
- Romosozumab
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- UCB Biopharma SRL
Osteoporosis
Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
The purpose of this study is to evaluate the effects of teriparatide on skeleton images in postmenopausal women with osteoporosis. Teriparatide is a bone formation agent that stimulates the production of new bone in the skeleton.
- Trial name
- NCT00259298
- Testing
- teriparatide
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment.
- Trial name
- NCT02598934
- Testing
- Ibandronate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.
- Trial name
- NCT02157948
- Testing
- Denosumab (CP2), Denosumab (CP4)
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 394 people
- Sponsor
- Amgen
Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
The purpose of this study is to assess to what extent sequential treatment with odanacatib results in incremental gains in bone mineral density (BMD) over time in female participants who have received at least 3 years of…
- Trial name
- NCT01803607
- Testing
- odanacatib
- Volunteers
- 135 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with…
- Trial name
- PEAK (NCT00365456)
- Testing
- Parathyroid Hormone (PTH), Risedronate
- Where
- Denmark
- Volunteers
- 407 people
- Sponsor
- Takeda
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Study of Monthly Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00247273
- Testing
- risedronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 1,294 people
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis.
- Trial name
- NCT00529373
- Testing
- Odanacatib, Vitamin D3, Calcium carbonate
- Volunteers
- 16,071 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis, Postmenopausal, Back Pain
Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.
- Conditions
- Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
- Trial name
- NCT00343252
- Testing
- teriparatide, risedronate
- Where
- 72 sites in United States, Argentina and 11 more
- Volunteers
- 712 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
- Trial name
- NCT06079476
- Testing
- Romosozumab
- Where
- 10 sites in India
- Volunteers
- 100 people
- Sponsor
- Amgen
Osteoporosis
Safety and Tolerability of Odanacatib (0822-059)
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
- Trial name
- NCT01068262
- Testing
- Odanacatib
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postmenopausal Osteoporosis
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis.
- Trial name
- NCT05405725
- Testing
- ENZ215, Prolia
- Where
- 48 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 504 people
- Sponsor
- Enzene Biosciences Ltd.
Postmenopausal Osteoporosis, Osteopenia
Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis
The overall objective of the study is to compare treatment with the ASTRA TECH Implant System, OsseoSpeed™ implant in the maxilla of postmenopausal women with and without systemic osteoporosis.
- Conditions
- Postmenopausal Osteoporosis, Osteopenia, Jaw, Edentulous, Partially
- Trial name
- NCT00745121
- Testing
- OsseoSpeed™
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 103 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Hypercalciuria, Hypercalciuria, Familial Idiopathic
The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement…
- Conditions
- Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
- Trial name
- NCT01928082
- Testing
- Transdermal estradiol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Post Menopausal Osteoporosis
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when…
- Trial name
- NCT01674621
- Testing
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg)
- Where
- 9 sites in United States, Denmark and 2 more
- Volunteers
- 250 people
- Sponsor
- Radius Health, Inc.